NCT06827782View on ClinicalTrials.gov

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Refractory/Recurrent Central Nervous System Lymphoma
Interventions
BIOLOGICAL

anti-CD19 CAR-NK cells

lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR

Trial Locations (1)

Unknown

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER